Clinical Trial Update: Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD

View source ↗

Summary

A completed clinical trial updated quality-of-life outcomes in adults over 18 with severe COPD treated with Daxas (roflumilast).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daxas (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Severe COPD | Status: COMPLETED